Biomerica Company Insiders
BMRA Stock | USD 3.40 0.25 7.94% |
Biomerica employs about 64 people. The company is managed by 7 executives with a total tenure of roughly 54 years, averaging almost 7.0 years of service per executive, having 9.14 employees per reported executive. Analysis of Biomerica's management performance can provide insight into the company performance.
Zackary Irani Chairman Chairman, CEO and Pres |
Biomerica | Build AI portfolio with Biomerica Stock |
Biomerica Management Team Effectiveness
The company has return on total asset (ROA) of (0.3599) % which means that it has lost $0.3599 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.727) %, meaning that it created substantial loss on money invested by shareholders. Biomerica's management efficiency ratios could be used to measure how well Biomerica manages its routine affairs as well as how well it operates its assets and liabilities.Biomerica Workforce Comparison
Biomerica is rated third in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 344. Biomerica retains roughly 64.0 in number of employees claiming about 19% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.85) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.08) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.08. Biomerica Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomerica insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomerica's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biomerica insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Chin Eric over a month ago Insider Trading | ||
Lu Gary over three months ago Acquisition by Lu Gary of 155000 shares of Biomerica at 1.01 subject to Rule 16b-3 | ||
Emerson Jane over three months ago Acquisition by Emerson Jane of 20000 shares of Biomerica at 6.36 subject to Rule 16b-3 | ||
Moatazedi David over six months ago Acquisition by Moatazedi David of 32000 shares of Biomerica at 1.67 subject to Rule 16b-3 | ||
Coste Catherine over six months ago Acquisition by Coste Catherine of 85000 shares of Biomerica at 0.31 subject to Rule 16b-3 | ||
Allen Barbieri over six months ago Acquisition by Allen Barbieri of 1538 shares of Biomerica at 2.94 subject to Rule 16b-3 | ||
Allen Barbieri over a year ago Insider Trading | ||
Steven Sloan over a year ago Acquisition by Steven Sloan of 25000 shares of Biomerica at 6.36 subject to Rule 16b-3 |
Biomerica Notable Stakeholders
A Biomerica stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biomerica often face trade-offs trying to please all of them. Biomerica's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biomerica's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Zackary Irani | Chairman, CEO and Pres | Profile | |
Gary CPA | Principal CFO | Profile | |
Allen Barbieri | Independent Director | Profile | |
Hans Boehringer | VP RD | Profile | |
Steven Sloan | CFO Treasurer | Profile | |
Lucy Liu | Director Operations | Profile | |
Robert Carlson | Chief Officer | Profile |
About Biomerica Management Performance
The success or failure of an entity such as Biomerica often depends on how effective the management is. Biomerica management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biomerica management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biomerica management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection andor treatment of medical conditions and diseases worldwide. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California. Biomerica operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 64 people.
Please note, the presentation of Biomerica's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biomerica's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biomerica's management manipulating its earnings.
Biomerica Workforce Analysis
Traditionally, organizations such as Biomerica use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biomerica within its industry.Biomerica Manpower Efficiency
Return on Biomerica Manpower
Revenue Per Employee | 84.6K | |
Revenue Per Executive | 773.6K | |
Net Loss Per Employee | 93.4K | |
Net Loss Per Executive | 854K | |
Working Capital Per Employee | 86.4K | |
Working Capital Per Executive | 789.6K |
Complementary Tools for Biomerica Stock analysis
When running Biomerica's price analysis, check to measure Biomerica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomerica is operating at the current time. Most of Biomerica's value examination focuses on studying past and present price action to predict the probability of Biomerica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomerica's price. Additionally, you may evaluate how the addition of Biomerica to your portfolios can decrease your overall portfolio volatility.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |